A5091825921- Nonmelanoma Skin Cancer Studies
- Acne and Rosacea Treatments and Effects
- Skin Protection and Aging
- Nail Diseases and Treatments
- Dermatology and Skin Diseases
- Herpesvirus Infections and Treatments
- Sympathectomy and Hyperhidrosis Treatments
- Autoimmune Bullous Skin Diseases
- Drug-Induced Adverse Reactions
- Cutaneous Melanoma Detection and Management
- Interprofessional Education and Collaboration
- Antifungal resistance and susceptibility
- Psoriasis: Treatment and Pathogenesis
- Pharmacological Effects of Natural Compounds
- Natural Compound Pharmacology Studies
- Allergic Rhinitis and Sensitization
- Dermatologic Treatments and Research
- Nursing Roles and Practices
- Global Health Workforce Issues
- Fungal Biology and Applications
- Glycogen Storage Diseases and Myoclonus
- melanin and skin pigmentation
- Healthcare Education and Workforce Issues
- Body Contouring and Surgery
- Myofascial pain diagnosis and treatment
DermResearch (United States)
2017-2024
Laser and Skin Surgery Center of New York
2018
University of Arizona
2014-2018
University of Washington Medical Center
2003
Background The topical phosphodiesterase 4 inhibitor roflumilast has been studied in several dermatologic conditions. Objective Roflumilast foam 0.3% is being investigated as a treatment for seborrheic dermatitis (SD). Methods In this phase 3, double-blinded trial, patients with SD were randomly assigned (2:1 ratio) to once-daily or vehicle 8 weeks. primary efficacy outcome was Investigator Global Assessment (IGA) Success at week 8, defined IGA of 0 (Clear) 1 (Almost Clear) plus ≥2-point...
Current topical treatment options for seborrheic dermatitis are limited by efficacy and/or safety.To assess safety and of roflumilast foam, 0.3%, in adult patients with affecting the scalp, face, trunk.This multicenter (24 sites US Canada) phase 2a, parallel group, double-blind, vehicle-controlled clinical trial was conducted between November 12, 2019, August 21, 2020. Participants were (aged ≥18 years) a diagnosis 3-month or longer duration Investigator Global Assessment (IGA) score 3...
Abstract Background RPT193 is an orally administered small molecule antagonist of the human C‐C motif chemokine receptor 4 (CCR4) that inhibits migration and downstream activation T‐helper Type 2 (Th2) cells. We investigated single‐ multiple‐ascending doses in healthy subjects, multiple subjects with moderate‐to‐severe atopic dermatitis (AD). Methods This was a first‐in‐human randomized, placebo‐controlled Phase 1a/1b monotherapy study (NCT04271514) to evaluate safety, tolerability,...
Abstract Tirbanibulin ointment 1% is approved in the United States and Europe for treatment of actinic keratosis with demonstrated efficacy, safety, tolerability when applied over a field up to 25 cm 2 . This Phase 1 maximal‐use trial determines plasma pharmacokinetics, tirbanibulin 100 face or balding scalp adults keratosis. Twenty‐eight patients self‐applied once daily single 5‐day course. On Day 5, mean maximum concentration was 1.06 ng/mL area under concentration‐time curve during dosing...
A small-molecule injectable drug, CBL-514, has shown promising efficacy and safety for subcutaneous fat reduction. To further evaluate the of CBL-514 abdominal In this single-blind, randomized, parallel-group, placebo-controlled Phase 2 trial, 76 participants were randomized (2:1) to receive up four treatments (2mg/cm², maximum 600mg/treatment) or placebo, administered subcutaneously abdomen every 4 weeks. Two follow-up visits conducted at 8 weeks post-final treatment. Changes in thickness...
Tapinarof is a novel topical therapeutic aryl hydrocarbon receptor modulating agent in development for the treatment of psoriasis and atopic dermatitis. This multicenter, open-label trial assessed safety, tolerability, pharmacokinetics (PK), efficacy tapinarof cream 1% once daily (QD) under maximal use conditions extensive plaque psoriasis. Adults with baseline Physician Global Assessment (PGA) score ≥ 3 body surface area (BSA) involvement 20% received QD 29 days. Safety tolerability...
Scalp psoriasis affects most patients with psoriasis, but it can be difficult to treat.To evaluate the efficacy and safety of once-daily roflumilast foam 0.3% on scalp body psoriasis.In a phase IIb randomized controlled trial, adults adolescents aged ≥ 12 years were (2 : 1) or vehicle for 8 weeks. The primary endpoint was Investigator Global Assessment (S-IGA) success (score 'clear' 'almost clear' plus 2-grade improvement from baseline) at week 8. Safety tolerability also...
Current field-directed treatments of actinic keratosis (AK), a pre-malignant condition, are often limited by severe local reactions and/or complex treatment. Tirbanibulin, novel potent anti-proliferative synthetic agent that inhibits tubulin polymerization and Src kinase signalling, is being developed as convenient, safe, effective field treatment keratosis.A short course tirbanibulin ointment 1% safely reduces AK lesions.In the Phase 1 study, 4 cohorts with forearm lesions received over 25...
This phase 2a trial investigated the efficacy of NFX-179 Topical Gel, a metabolically labile MEK inhibitor, in treatment cutaneous neurofibromas (cNFs) neurofibromatosis type 1. Forty-eight participants were randomized to four arms: Gel 0.05%, 0.15%, and 0.5% or vehicle applied once daily five target cNFs for 28 days. Treatment with resulted dose-dependent reduction p-ERK levels at day 28, 47% decrease group compared (
With a paucity of literature on professional organization membership by nurse practitioners (NPs), the authors base discussion personal benefits associated with focusing clinicians other than NPs and their experiences as members multiple organizations. Membership is described related to NP socialization, engagement, networking, mentorship, advocacy, policy, leadership development, research dissemination, volunteerism. In addition encouraging active participation in one or more organizations,...
BACKGROUND Seborrheic keratosis (SK) is a common benign skin tumor, yet no topical treatments are approved in the United States. OBJECTIVE To evaluate proprietary, stabilized, high-concentration hydrogen peroxide–based solution A-101 (32.5% and 40% concentrations) for treatment of facial SK lesions. MATERIALS AND METHODS In this multicenter, double-blind, vehicle-controlled study, eligible subjects were randomly assigned to receive up 2 40%, 32.5%, or vehicle applied single lesion. The...
Topical antifungals may be considered to treat onychomycosis with minimal risk of systemic side effects. In this study, we assess the safety, tolerability, exposure, and pharmacokinetic characteristics topical terbinafine hydrochloride 10% solution (MOB015B) in adults moderate-to-severe onychomycosis. Clinically mycologically confirmed patients toenail (
Hyperhidrosis is a common medical condition which can have significant impact on quality of life. Umeclidinium (UMEC) long-acting muscarinic antagonist (LAMA) developed as dermal formulation.This 2-week, double-blind, randomized, vehicle-controlled study evaluated systemic exposure, safety and tolerability topically administered UMEC in subjects with primary axillary hyperhidrosis. Clinical effect was secondary objective, measured by gravimetry the hyperhidrosis disease severity scale...
The HeartMate VE LVAS is a device that provides cardiovascular support to patients waiting for heart transplant. authors describe the development of tool used educate who are discharged home with this device.A teaching documentation was created education Vented Electric Left Ventricular Assist System (VE LVAS, Thoratec Corp, Pleasanton, Calif ). This allows those wait at rather than in hospital. In past, could hospital up year, unable be without Convalescing recover from some debilitating...
The focus of this column is the interface between policy and end-of-life care, particularly as provided by advanced nurse practitioners. complexities along with barriers in practice can diminish quality life for patients their families. Changes are needed to enable practitioners full scope a way that benefits families at end-of-life. Three areas relevant nursing care addressed: practice, reimbursement, prescribing practices. Other recommendations discussed.
Purpose: To evaluate oral setipiprant versus placebo for scalp hair growth in men with androgenetic alopecia (AGA). Patients and Methods: Males aged 18 to 49 years AGA were enrolled a double-blind, multicenter, 32-week, phase 2a trial; randomized twice-daily (BID) 1000-mg (2× 500 mg total daily dose of 2000 mg) tablets or 24 weeks; assessed at weeks 4, 8, 16, 24, week 32 follow-up. The study initially included finasteride 1-mg once-daily group, removed by protocol amendment. Changes from...
There is a paucity of literature covering patient-reported outcomes treatments for truncal acne. Trifarotene 50 μg/g cream novel retinoid molecule approved once-daily topical treatment facial and acne vulgaris. As physicians are starting to gain real-world experience with this treatment, their access reporting from the patient's perspective provides valuable adjunct pivotal studies. We report case series three subjects moderate treated trifarotene on face, shoulders, upper back anterior...